查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750662

美國介入性心臟病學和周邊血管市場：市場規模、佔有率、趨勢分析（按產品和應用）、細分市場預測（2025-2030 年）

U.S. Interventional Cardiology And Peripheral Market Size, Share & Trends Analysis Report By Product, By Application, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 160 Pages | 商品交期: 2-10個工作天內

價格

美國介入性心臟病學和周邊血管市場的成長和趨勢：

根據Grand View Research, Inc.的最新報告，美國介入性心臟病學和周邊血管市場規模預計到2030年將達到111.9億美元，預測期內的複合年成長率為6.0%。

心血管和周邊血管疾病負擔的不斷加重、人們對微創手術的日益偏好以及設備技術的不斷進步，共同推動市場的發展。老年人口的不斷成長、糖尿病和高血壓盛行率的不斷上升以及支持性報銷政策的不斷訂定，進一步推動了市場的成長。

心血管疾病的日益普及推動了介入性心臟病學和周邊血管市場的持續成長。許多患者在不同階段被診斷出患有冠狀動脈和周邊動脈阻塞，促使他們及時接受醫療干預。隨著診斷技術的進步和定期篩檢，疾病檢測能力不斷提升，治療重點正轉向更早、侵入性更低的治療途徑。

血管成形術、支架置入術和血栓切除術等介入性手術如今已成為有效管理這些疾病的核心手段。美國疾病管制與預防中心（CDC）於2024年10月報告稱，心臟病仍然是美國最大的死亡原因，2022年死亡人數達702,880人，相當於五分之一的死亡病例。冠狀動脈疾病（CAD）是最常見的疾病，造成超過371,000人死亡。高血壓、高膽固醇、吸菸、糖尿病、肥胖和缺乏運動等風險因素被認為是主要原因。

美國介入性心臟病學和周邊血管市場：概述

  • 按產品分類，冠狀動脈支架部分預計在 2024 年佔據最大的收入佔有率，達到 41.5%。
  • 該領域的成長得益於經皮冠狀動脈介入治療 (PCI) 的日益普及、藥物釋放型支架技術的持續進步以及美國支持微創心血管手術的優惠報銷政策。
  • 根據應用，血管成形術部分將在 2024 年佔據最大的收益佔有率，為 59.2%。此部分的顯著成長主要得益於動脈粥狀硬化性心血管疾病的高盛行率、藥物釋放型球囊支架的使用增加以及對微創血管重組手術的需求不斷成長。
  • 新興企業正在採取多種策略，例如推出新產品來加強其市場地位。
  • 2024年2月，Biotronic在美國推出了Micro Rx導管，支援PCI期間的導管導引線手術。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章美國介入性心臟病學和周邊血管市場：促進因素、趨勢和範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 美國介入性心臟病學和周邊血管市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章美國介入性心臟病學和周邊血管市場：按產品分類的估計和趨勢分析

  • 產品細分儀表板
  • 美國介入性心臟病學和周邊血管市場：按產品分類的差異分析
  • 美國介入性心臟病學和周邊血管市場規模和趨勢分析（按產品）（2018-2030）
  • 干涉導管
  • 微導管
    • 微導管支援
    • 輸送微導管
    • 其他
  • 導管導引線
  • 外周支架
    • 自膨脹
    • 球囊擴張
    • 藥物釋放型支架
  • 冠狀動脈支架
    • 生物可吸收支架
    • 藥物釋放型支架
    • 裸金屬支架
  • PTCA球囊導管
  • 動脈粥狀硬化斑塊切除設備
  • 慢性完全閉塞裝置
  • 合成外科移植物
  • 栓塞保護裝置
  • 下腔靜脈過濾器
  • PTA球囊導管
  • 血栓除去裝置

第5章美國介入性心臟病學和周邊血管市場：應用預測和趨勢分析

  • 應用程式細分儀表板
  • 美國介入性心臟病學和周邊血管市場：應用差異分析
  • 美國介入性心臟病學及周邊血管市場規模及應用趨勢分析（2018-2030）
  • 血管成形術
  • 先天性心臟疾病的矯正
  • 血栓切除術
  • 瓣環成形手術
  • 經皮瓣膜修復
  • 其他

第6章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要企業熱力圖分析（2024年）
  • 公司簡介
    • B. Braun SE
    • BD
    • Cardinal Health
    • Medtronic
    • Teleflex Incorporated
    • WL Gore &Associates Inc.
    • Cook
    • Boston Scientific Corporation
    • AngioDynamics
    • Abbott
    • OrbusNeich Medical Group Holdings Limited
Product Code: GVR-4-68040-581-2

U.S. Interventional Cardiology and Peripheral Market Growth & Trends:

The U.S. interventional cardiology and peripheral market size is anticipated to reach USD 11.19 billion by 2030, growing at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growing burden of cardiovascular & peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology. Increasing geriatric population, higher rates of diabetes & hypertension, and supportive reimbursement policies further fuel market expansion.

The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.

Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.

U.S. Interventional Cardiology And Peripheral Market Report Highlights:

  • Based on product, the coronary stents segment accounted for the largest revenue share of 41.5% in 2024.
  • The segment growth is driven by increasing adoption of Percutaneous Coronary Interventions (PCI), continuous advancements in drug-eluting stent technologies, and favorable reimbursement policies supporting minimally invasive cardiovascular procedures in the U.S.
  • Based on application, the angioplasty segment accounted for the largest revenue share of 59.2% in 2024. The significant growth of this segment is largely driven by the high prevalence of atherosclerotic cardiovascular disease, increasing use of drug-eluting balloons & stents, and rising demand for minimally invasive revascularization procedures.
  • Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.
  • In February 2024, Biotronik launched the Micro Rx catheter in the U.S. to support guidewire procedures during PCI, reflecting ongoing technological progress and sustained market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Interventional Cardiology and Peripheral Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Interventional Cardiology and Peripheral Market: Product Movement Analysis
  • 4.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Interventional Catheters
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Microcatheters
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Support Microcatheters
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Delivery Microcatheters
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Guidewires
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Peripheral Stents
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. Self-Expanding
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Balloon-Expandable
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.4. Drug-Eluting Stents
      • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Coronary Stents
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.2. Bioabsorbable Stents
      • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.3. Drug Eluting Stents
      • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.4. Bare Metal Stents
      • 4.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. PTCA Balloon Catheters
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Atherectomy Devices
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Chronic Total Occlusion Devices
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Synthetic Surgical Grafts
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Embolic Protection Devices
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. IVC Filters
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.15. PTA Balloon Catheters
    • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.16. Thrombectomy Devices
    • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. Interventional Cardiology and Peripheral Market: Application Movement Analysis
  • 5.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Angioplasty
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Congenital Heart Defect Correction
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Thrombectomy
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Valvuloplasty
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Percutaneous Valve Repair
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Key company heat map analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. B. Braun SE
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Product benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. BD
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Product benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Cardinal Health
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Product benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Medtronic
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Product benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Teleflex Incorporated
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Product benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. W. L. Gore & Associates Inc.
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Product benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Cook
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Product benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Boston Scientific Corporation
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Product benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. AngioDynamics
      • 6.4.9.1. Company overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Product benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Abbott
      • 6.4.10.1. Company overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Product benchmarking
      • 6.4.10.4. Strategic initiatives
    • 6.4.11. OrbusNeich Medical Group Holdings Limited
      • 6.4.11.1. Company overview
      • 6.4.11.2. Financial performance
      • 6.4.11.3. Product benchmarking
      • 6.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. interventional cardiology and peripheral market, by region, 2018 - 2030 (USD Million)
  • Table 3 U.S. interventional cardiology and peripheral market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. interventional cardiology and peripheral market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. interventional cardiology and peripheral market: market outlook
  • Fig. 10 U.S. interventional cardiology and peripheral competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. interventional cardiology and peripheral market driver impact
  • Fig. 16 U.S. interventional cardiology and peripheral market restraint impact
  • Fig. 17 U.S. interventional cardiology and peripheral market strategic initiatives analysis
  • Fig. 18 U.S. interventional cardiology and peripheral market: Product movement analysis
  • Fig. 19 U.S. interventional cardiology and peripheral market: Product outlook and key takeaways
  • Fig. 20 Interventional catheters estimates and forecast, 2018 - 2030
  • Fig. 21 Microcatheters estimates and forecast, 2018 - 2030
  • Fig. 22 Support microcatheters estimates and forecast, 2018 - 2030
  • Fig. 23 Delivery microcatheters estimates and forecast, 2018 - 2030
  • Fig. 24 Others estimates and forecast, 2018 - 2030
  • Fig. 25 Guidewires estimates and forecast, 2018 - 2030
  • Fig. 26 Peripheral stents estimates and forecast, 2018 - 2030
  • Fig. 27 Self-expanding estimates and forecast, 2018 - 2030
  • Fig. 28 Balloon-expandable estimates and forecast, 2018 - 2030
  • Fig. 29 Drug-eluting stents estimates and forecast, 2018 - 2030
  • Fig. 30 Coronary stents estimates and forecast, 2018 - 2030
  • Fig. 31 Bioabsorbable stents estimates and forecast, 2018 - 2030
  • Fig. 32 Drug eluting stents estimates and forecast, 2018 - 2030
  • Fig. 33 Bare metal stents estimates and forecast, 2018 - 2030
  • Fig. 34 PTCA balloon catheters estimates and forecast, 2018 - 2030
  • Fig. 35 Atherectomy devices estimates and forecast, 2018 - 2030
  • Fig. 36 Chronic total occlusion devices estimates and forecast, 2018 - 2030
  • Fig. 37 Synthetic surgical grafts estimates and forecast, 2018 - 2030
  • Fig. 38 Embolic protection devices estimates and forecast, 2018 - 2030
  • Fig. 39 IVC filters estimates and forecast, 2018 - 2030
  • Fig. 40 PTA balloon catheters estimates and forecast, 2018 - 2030
  • Fig. 41 Thrombectomy devices estimates and forecast, 2018 - 2030
  • Fig. 42 U.S. interventional cardiology and peripheral market: Application movement analysis
  • Fig. 43 U.S. interventional cardiology and peripheral market: Application outlook and key takeaways
  • Fig. 44 Angioplasty estimates and forecast, 2018 - 2030
  • Fig. 45 Congenital heart defect correction estimates and forecast, 2018 - 2030
  • Fig. 46 Thrombectomy estimates and forecast, 2018 - 2030
  • Fig. 47 Valvuloplasty estimates and forecast, 2018 - 2030
  • Fig. 48 Percutaneous valve repair estimates and forecast, 2018 - 2030
  • Fig. 49 Others estimates and forecast, 2018 - 2030